https://startupxplore.com/en/investors/morphosys-ag
MorphoSys AG profile at Startupxplore
morphosysagprofile
https://www.biospace.com/morphosys-to-present-data-on-tafasitamab-at-the-ash-virtual-annual-meeting-and-exposition
MorphoSys to Present Data on Tafasitamab at the ASH Virtual Annual Meeting and Exposition - BioSpace
https://robinhood.com/us/en/stocks/MORZZZ/
MorphoSys Contra: MORZZZ Stock Price Quote & News | Robinhood
You can watch MORZZZ and buy and sell other stocks, ETFs, and their options commission-free on Robinhood. Change the date range, see whether others are buying...
stock pricemorphosyscontraquotenews
https://www.benzinga.com/news/earnings/23/05/32168714/preview-morphosyss-earnings
Preview: MorphoSys's Earnings - Benzinga
previewmorphosysearningsbenzinga
https://www.fiercebiotech.com/biotech/after-being-snapped-up-by-alexion-syntimmune-ceo-joins-morphosys
After being snapped up by Alexion, Syntimmune's CEO joins MorphoSys | Fierce Biotech
Jun 25, 2019 - New York rare disease biotech Syntimmune has had a roller-coaster few years, losing CEOs, gaining new ones and then being snapped up by Alexion Pharmaceuticals...
https://www.biospace.com/morphosys-ag-publication-pursuant-to-ss-sect-1-wphg-the-german-securities-trading-act-with-the-aim-of-pan-european-distribution
MorphoSys AG: Publication Pursuant to SS Sect.1 WpHG (the German Securities Trading Act) With the...
https://www.biospace.com/morphosys-to-showcase-phase-3-manifest-2-data-on-pelabresib-in-myelofibrosis-in-oral-presentation-at-2023-ash-annual-meeting
MorphoSys To Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation...
Jul 17, 2024 - MorphoSys AG announced that data from the Phase 3 MANIFEST-2 trial of pelabresib, an investigational BET inhibitor, in combination with the JAK inhibitor...
https://www.sec.gov/rules-regulations/no-action-interpretive-exemptive-letters/division-corporation-finance-no-action/morphosys-ag-040924
SEC.gov | MorphoSys AG
sec govmorphosysag
https://www.xtb.com/en/market-analysis/morphosys-gains-37-amid-rumours-of-possible-takeover-by-novartis
MorphoSys gains 37% amid rumours of possible takeover by Novartis | XTB
Drug maker Novartis AG (NOVN.CH) is in advanced talks to acquire MorphoSys AG (MOR.DE), two people familiar with the matter told Reuters on Monday. The sources...
morphosysgains37amidrumours
https://www.fool.com/earnings/call-transcripts/2021/05/06/morphosys-ag-mor-q1-2021-earnings-call-transcript/
MorphoSys AG (MOR) Q1 2021 Earnings Call Transcript | The Motley Fool
May 7, 2021 - MOR earnings call for the period ending March 31, 2021.
earnings call transcriptq1 2021the motleymorphosysag
https://www.fiercebiotech.com/keyword/morphosys
MorphoSys | Fierce Biotech
morphosysfiercebiotech
https://www.biospace.com/morphosys-appoints-jean-paul-kress-m-d-as-new-chief-executive-officer
MorphoSys Appoints Jean-Paul Kress, M.D., as New Chief Executive Officer - BioSpace
Jun 25, 2019 - MorphoSys AG announced that its Supervisory Board has appointed Jean-Paul Kress, M.D., as its new Chief Executive Officer.
https://www.biospace.com/incyte-and-morphosys-announce-acceptance-by-health-canada-of-the-new-drug-submission-for-tafasitamab
Incyte and MorphoSys Announce Acceptance by Health Canada of the New Drug Submission for...